Back to Search
Start Over
COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy
- Source :
- Thrombosis Research
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Highlights • COVID-19 patients are at increased risk of thromboembolic complications. • Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events. • The bleeding risk is highest for patients treated with therapeutic anticoagulation.
- Subjects :
- Male
medicine.medical_specialty
2019-20 coronavirus outbreak
Time Factors
Coronavirus disease 2019 (COVID-19)
Letter to the Editors-in-Chief
Hemorrhage
030204 cardiovascular system & hematology
Risk Assessment
Anticoagulation
03 medical and health sciences
0302 clinical medicine
Risk Factors
Thromboembolism
Coagulopathy
Humans
Medicine
Thromboprophylaxis
Aged
Retrospective Studies
COVID
Aged, 80 and over
Escalated-dose
business.industry
Mortality rate
Anticoagulants
COVID-19
Thrombosis
Retrospective cohort study
Venous Thromboembolism
Hematology
Middle Aged
medicine.disease
COVID-19 Drug Treatment
Treatment Outcome
Increased risk
030220 oncology & carcinogenesis
Emergency medicine
Female
VTE
business
Risk assessment
Subjects
Details
- ISSN :
- 00493848
- Volume :
- 196
- Database :
- OpenAIRE
- Journal :
- Thrombosis Research
- Accession number :
- edsair.doi.dedup.....b9feccea6df9e94879468e6ba240c2ea
- Full Text :
- https://doi.org/10.1016/j.thromres.2020.10.004